OCT DACH 2023

ICON delivers operational and consulting services to achieve product authorisation, through the strategic design and delivery of real world evidence studies and late phase research.

Medical imaging endpoints can provide objective evidence of a drug’s safety and efficacy across all phases of development.

Early phase patient trials have a specific set of criteria that can be complex to set up and manage.

Helping biotech meet critical milestones.

Cassandra is ICON’s system for predicting EMA and FDA post-marketing requirements (PMRs).

Ensuring the highest levels of safety and accuracy in your trials.

ICON delivers high quality, harmonised data from a global network of laboratories.

Supporting precision medicine programs across all phases of drug diagnostic co-development.

Innovative early phase solutions that will advance your drug development strategy.

Lessons learned and timelines to approval based on experience so far in the Netherlands.

Tailored solutions to accelerate clinical trial success.

ICON offers a one stop solution for drug development, enabling our sponsors to move through the clinical development stages sooner, significantly saving both study time and costs.

What companies must consider when developing an asset.

In this whitepaper, we explore the ways we can look at partnerships through a cultural lens and how we can harness that culture to drive progress toward our shared objectives.

Speed up timelines and reduce costs.

During this webinar we will outline the EU CTR process, sharing our experience of early phase trial submissions so far.